Curida, Small Molecules and Biologics CDMO, Secures Private Equity Investment from Signet Healthcare Partners
April 16 2024 - 7:00AM
Business Wire
Integrated provider of drug development and manufacturing
services to leverage Signet’s pharma services expertise for
business growth.
Curida Holding AS (“Curida”) has announced a significant growth
investment from Signet Healthcare Partners (“Signet”), a New
York-based healthcare private equity firm. This strategic
partnership will enable Curida to accelerate its expansion plans,
including enhancing facility capabilities and growing its industry
position.
Established in 2015 and headquartered in Oslo, Norway, Curida is
an integrated Contract Development and Manufacturing Organization
(“CDMO”) specializing in the use of blow-fill-seal (“BFS”) and
nasal spray technologies, as well as antibody manufacturing. Curida
provides outsourced development and manufacturing of aseptic and
non-aseptic liquid BFS and nasal spray formatted drugs, and serves
the diagnostics industry with monoclonal antibodies. Curida’s
customer base ranges from small to medium-sized pharmaceutical,
medical devices, and biotech companies, delivering solutions in
drug development and GMP manufacturing globally.
In conjunction with Signet’s investment, Signet is joining the
Board of Directors, and Ole J. Dahlberg has been appointed as
Chairman of the Board. Dahlberg has more than 20 years of
experience from leadership roles in the life science market and is
former Vice President & General Manager at Thermo Fisher
Scientific in California, USA. Dahlberg stated, “We are very
pleased to welcome Signet as a significant shareholder in Curida.
Signet brings strong relevant industry experience and a track
record of CDMO investing. Signet is co-investing alongside Curida’s
existing shareholders Canica, Investinor, Klaveness, and Farvatn.
We are excited by the opportunity to further accelerate innovation
and advance productivity for our pharma and biotech customers in
their work to deliver medicines and therapeutics to benefit
patients. On behalf of the board, I want to thank Per Thoresen, who
has been acting Chairman of the Board and for his valuable
contributions to Curida over the past 9 years.”
Additionally, the Board has appointed Anders Larsson, the
Company’s Chief Operating Officer, as Chief Executive Officer,
effective May 1st, 2024. Larsson comes with extensive experience in
management, operations, and strategic development from the pharma
industry. His former roles include CEO of Boots Pharmacy/Alliance
Healthcare in Norway (Cencora). In addition, Larsson has experience
from various roles in the food & beverage industry with Orkla
and Carlsberg. Larsson holds an MSc in Chemical Engineering from
Chalmers University and Imperial College and a BSc in Finance from
Gothenburg University.
Signet Managing Director Nikhil Puri said, “We are proud to
partner with Curida and support their robust growth strategy. The
Company’s strong values, commitment to excellence, and strategic
vision align nicely with our investment philosophy. We look forward
to contributing to Curida’s success in the coming years. We were
attracted to Curida due to its strong, differentiated manufacturing
capabilities, customer-centric approach, and management team
strength. We see a strong opportunity for Signet to leverage its
network and prior CDMO investment experience to accelerate
growth.”
DNB Markets served as financial advisor, and Advokatfirmaet
Simonsen Vogt Wiig served as legal advisor to Curida. Sheppard,
Mullin, Richter & Hampton LLP and Advokatfirmaet Selmer served
as legal advisors to Signet. Terms of the transaction were not
disclosed.
About Curida Group
Curida offers contract development and manufacturing solutions
to European pharmaceutical and biotech companies globally. Curida
focuses on aseptic and non-aseptic liquid manufacturing and
specializes in blow-fill-seal (“BFS”) and nasal spray technologies
to serve the Small Molecules pharmaceutical and medical device
market. For biologics, Curida offers upstream- and downstream
processing of monoclonal antibodies for in-vitro diagnostics
(“IVD”). For more information, visit www.curida.no
About Signet Healthcare Partners
Headquartered in New York, NY, Signet is an established provider
of growth capital to innovative healthcare companies. SIGNET
invests in commercial-stage healthcare companies that are revenue
generating or preparing for commercial launch. The firm invests
primarily in pharmaceutical and medical device companies. As an
active investor, Signet partners closely with its companies to
build their value including facilitating activities between
portfolio companies. During Signet's 25-year history, the firm has
developed a strong reputation and track record of successful
healthcare investments. Signet has raised funds with total capital
commitments of over $600 million and has invested in more than 55
companies. For more information, visit
www.signethealthcarepartners.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240416093461/en/
Curida Holding AS post@curida.no